Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States

Kaye, Deborah R.; Khilfeh, Ibrahim; Muser, Erik; Morrison, Laura; Kinkead, Frederic; Lefebvre, Patrick; Pilon, Dominic; George, Daniel

doi:10.1080/13696998.2024.2323901

Journal of Medical Economics

2024

DOI: 10.1080/13696998.2024.2323901

|View full text |Cite|

Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States

Deborah R. Kaye,

Ibrahim Khilfeh,

Erik Muser

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer

Miura,

Yamamoto,

Okuyama

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveWe aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real‐world big data included in The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data, covering most of the clinical practices throughout Japan.MethodsUsage data for outpatient prescriptions from 2016 to 2021 were extracted from the NDB Open Data. Among the 459,610 million tablets/capsules prescribed, prostate cancer‐specific agents (bicalutamide, estramustine phosphate, flutamide, abiraterone, enzalutamide, apalutamide, and darolutamide) were selected to investigate the trends of usage and medical costs.ResultsIn total, 764.8 billion medications were recorded. Among these, standard dose‐adjusted prescriptions for bicalutamide, abiraterone, enzalutamide, apalutamide, darolutamide, and other vintages (estramustine phosphate, flutamide) was 276, 14.2, 18.1, 2.19, 0.34, and 20.3 million, respectively. The usage of ARSI increased significantly from 6.1% in 2016 to 16% in 2021. The medical costs for prostate cancer‐specific agents increased significantly (1.8‐fold) from 2016 to 2021. Despite the limited usage of ARSIs, a majority of the medical costs had been spent on ARSIs. Medical costs associated with ARSIs increased significantly from 59% to 89% (p < 0.001).ConclusionARSI usage and medical costs associated with prostate cancer increased significantly from 2016 to 2021. Despite the limited use of ARSIs, a considerable proportion of the medical costs for prostate cancer‐specific agents had been spent on ARSIs.

show abstract

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer

Miura,

Yamamoto,

Okuyama

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Unveiling the chasm of economic burden from metastatic prostate cancer through a nationwide retrospective cohort study

Kang,

Kwak,

Choo

et al. 2024

Current Medical Research and Opinion

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States

Cited by 2 publications

References 30 publications

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer

Unveiling the chasm of economic burden from metastatic prostate cancer through a nationwide retrospective cohort study

Contact Info

Product

Resources

About